Business Context and Reporting Period
Bon Natural Life Limited, a bio-ingredient solutions provider based in Xi'an, China, announced its unaudited interim financial results for the six months ended March 31, 2025. The company manufactures functional active ingredients extracted from natural herbs for the functional food, personal care, cosmetic, and pharmaceutical industries. The filing was submitted on September 29, 2025.
Key Financial Metrics
| Metric | Six Months Ended March 31, 2025 | Six Months Ended March 31, 2024 |
|---|---|---|
| Revenue | $7,949,845 | $10,183,553 |
| Gross Profit | $1,907,848 | $2,968,437 |
| Gross Margin | 24.0% | 29.1% |
| Income from Operations | $284,050 | $84,505 |
| Net Income (Loss) | $135,911 | ($41,798) |
| EPS (Basic) | $0.56 | ($0.20) |
| Cash and Cash Equivalents (End of Period) | $8,894,053 | $717,879 |
| Net Cash Used in Operating Activities | ($4,295,567) | ($1,884,173) |
| Net Cash Provided by Financing Activities | $12,322,244 | $2,511,853 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 21.9% ($2.23 million) year-over-year. This was driven by a 97.6% drop in health supplement sales and a 68.9% drop in bioactive food ingredient sales.
- Fragrance Compound Surge: Revenue from fragrance compounds increased by 553.9% to $5.66 million, now representing 71.3% of total revenue. This growth was fueled by a 1,341.3% increase in sales volume of Perilla frutescens extract.
- Profitability Improvement: Despite lower revenue, the company turned a net loss of $41,798 in 2024 into a net income of $135,911 in 2025. Operating income increased by 236.1%.
- Expense Reduction: Total operating expenses decreased by 43.7%. Notably, R&D expenses dropped 89.2% due to the cessation of outsourced R&D activities, and G&A expenses fell 22.8% due to reduced professional service fees.
- Liquidity Position: Cash on hand increased significantly to $8.89 million, primarily due to $10.54 million in proceeds from a public offering of Class A Ordinary Shares and net borrowings.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management is pivoting focus toward fragrance compounds, specifically Perilla frutescens extract, which has seen strong market adoption. Conversely, the company is reducing exposure to the declining powder drink market.
- New Product Strategy: The company is launching a new product line integrating Chinese medicine into bioactive food ingredients. To penetrate this market, they have adopted lower pricing strategies, which contributed to the decline in gross margins for this segment.
- Operational Efficiency: The company has shifted R&D from external consulting to internal development efforts to control costs. Staff headcount in sales was reduced from 8 to 6.
- Forward-Looking Risks: The filing includes standard warnings that actual results may differ materially from projections due to competitive pressures, raw material price fluctuations, and market demand volatility.
- Unusual Items: A significant portion of the increase in long-term other receivables ($14.5 million) relates to proceeds from the sale of a Gansu subsidiary, expected to be collected over two years. Additionally, government subsidies dropped to zero in the current period.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of the 71.3% revenue reliance on fragrance compounds and the specific demand drivers for Perilla frutescens extract.
- Cash Flow Quality: Confirm the timing and collectability of the $14.5 million receivable from the Gansu subsidiary sale, as operating cash flow remains negative despite net income.
- Margin Compression: Assess the long-term impact of the 5.2% decline in gross margin and the pricing strategy for new Chinese medicine-integrated products.
- Debt Obligations: Review the terms of the short-term loans that increased interest expense by 14.5% and the repayment schedule.
- Share Consolidation: Note that EPS figures are retroactively restated to reflect a 1-for-25 share consolidation effective May 19, 2025.